Capital Advisors Inc. OK Has $12.21 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Capital Advisors Inc. OK lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 310,270 shares of the company’s stock after buying an additional 9,681 shares during the quarter. Capital Advisors Inc. OK’s holdings in CRISPR Therapeutics were worth $12,212,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics in the 3rd quarter worth about $43,000. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics in the 4th quarter worth about $39,000. Western Pacific Wealth Management LP raised its stake in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Finally, Eastern Bank acquired a new stake in CRISPR Therapeutics in the 3rd quarter worth about $70,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CRSP shares. Chardan Capital reiterated a “buy” rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Bank of America decreased their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, January 14th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $77.59.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $39.62 on Wednesday. The firm’s 50 day simple moving average is $42.45 and its 200 day simple moving average is $46.40. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $91.10. The company has a market cap of $3.38 billion, a PE ratio of -14.00 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. Equities research analysts expect that CRISPR Therapeutics AG will post -5.08 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.